Abetis 20 mg (Tablet)

Unit Price: ৳ 11.00 (5 x 10: ৳ 550.00)

Strip Price: ৳ 110.00

Medicine Details

Category	Details
Generic	Olmesartan medoxomil
Company	Aci limited
Also available as	Abetis 10 mg tablet Abetis 40 mg tablet

Formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme
Principal pressor agent of the renin-angiotensin system
Causes vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium
Blocks vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT 1 receptor in vascular smooth muscle
Has more than a 12,500-fold greater affinity for the AT 1 receptor than for the AT 2 receptor
Does not inhibit ACE (kininase II) or affect the response to bradykinin
Inhibits the negative regulatory feedback of angiotensin II on renin secretion

Usual recommended starting dose of 20 mg once daily when used as monotherapy
For patients requiring further reduction in blood pressure, the dose may be increased to 40 mg
No advantage in twice-daily dosing over the same total dose given once daily
No initial dosage adjustment recommended for elderly patients or for patients with moderate to marked renal impairment or hepatic dysfunction
May be administered with or without food
Safety and effectiveness in pediatric patients not established

No significant drug interactions reported for digoxin or warfarin in healthy volunteers
Bioavailability not significantly altered by the co-administration of antacids
Not metabolized by the cytochrome P450 system and has no effects on P450 enzymes
Possible deterioration of renal function when co-administered with NSAIDs, including selective COX-2 inhibitors

Contraindicated in patients who are hypersensitive to any component of the product

Evaluated for safety in more than 3825 patients
Incidence of adverse reactions similar to placebo
Overall frequency of adverse reactions not dose related
The rate of withdrawals due to adverse reactions was 2.4% of patients treated with the product
Most common adverse reaction: dizziness
Other adverse reactions occurred at an incidence of more than 1% of patients, but also occurred at similar or greater incidence in patients receiving placebo

Discontinue the product as soon as pregnancy is detected
Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus
Potential excretion in human milk, decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the mother

Changes in renal function may be anticipated in susceptible individuals
Treatment has been associated with oliguria, progressive azotemia, acute renal failure, and death especially in patients with severe congestive heart failure

No experience of overdose reported
Most likely effects of overdose: hypotension and tachycardia
Gastric lavage or induction of emesis may be considered if intake is recent
Clinically significant hypotension due to overdose requires active support of the cardiovascular system